Vanguard Personalized Indexing Management LLC Increases Stake in 23andMe Holding Co. (NASDAQ:ME)

Vanguard Personalized Indexing Management LLC raised its stake in shares of 23andMe Holding Co. (NASDAQ:ME) by 410.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 88,555 shares of the company’s stock after acquiring an additional 71,204 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in 23andMe were worth $35,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in ME. Levin Capital Strategies L.P. acquired a new position in 23andMe during the 2nd quarter valued at approximately $61,000. Wittenberg Investment Management Inc. raised its stake in 23andMe by 63.9% in the 1st quarter. Wittenberg Investment Management Inc. now owns 2,290,945 shares of the company’s stock worth $1,219,000 after acquiring an additional 893,552 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of 23andMe by 68.3% in the first quarter. China Universal Asset Management Co. Ltd. now owns 60,653 shares of the company’s stock worth $32,000 after purchasing an additional 24,604 shares during the last quarter. Finally, Mirador Capital Partners LP lifted its holdings in shares of 23andMe by 11.2% during the first quarter. Mirador Capital Partners LP now owns 340,946 shares of the company’s stock worth $181,000 after purchasing an additional 34,321 shares during the period. 36.10% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, TD Cowen lowered 23andMe from a “strong-buy” rating to a “strong sell” rating in a report on Wednesday, August 7th.

23andMe Stock Performance

ME opened at $0.37 on Wednesday. The company has a fifty day moving average of $0.35 and a two-hundred day moving average of $0.43. 23andMe Holding Co. has a fifty-two week low of $0.29 and a fifty-two week high of $1.02. The stock has a market capitalization of $180.91 million, a price-to-earnings ratio of -0.26 and a beta of 1.19.

23andMe (NASDAQ:ME) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.14) EPS for the quarter. 23andMe had a negative net margin of 317.03% and a negative return on equity of 83.22%. The business had revenue of $40.41 million during the quarter, compared to analysts’ expectations of $50.30 million.

23andMe Profile

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.